CD73 억제제 및 A2A/A2B 아데노신 수용체 억제제 병용 요법

• Main Authors: ALMAGRO JUAN CARLOS, ZHOU JING, WANG XIAOZHAO, LI YONG, STEWART SHAUN M, HUANG TAISHENG, BUONPANE REBECCA A, ZHU WENYU, QI CHAO, NASTRI HORACIO G, CARLSEN PETER NIELS, YAO WENQING, CHEN YINGNAN, WU LIANGXING, WANG HUI
• Format: Patent
• Language: Korean
• Published: 11.10.2022
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

CD73 억제제 및 아데노신 A2A 또는 A2B 수용체 억제제의 투여를 포함하는 병용 요법을 개시한다. 개시된 병용 요법은 예를 들어, 암, 염증성 질환, 심혈관 질환, 및 신경퇴행성 질환을 포함하는, 아데노신 수용체 및/또는 CD73의 활성과 관련된 질환의 치료에 유용하다. 항-CD73 항체 및 A2A/A2B 억제제를 또한 개시한다. Disclosed are combination therapies comprising administration of a CD73 inhibitor and an adenosine A2A or A2B receptor inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies and A2A/A2B inhibitors are also disclosed.